Drug Profile
Research programme: respiratory syncytial virus intranasal vaccine - Nobilon International/NVI
Latest Information Update: 30 Aug 2011
Price :
$50
*
At a glance
- Originator Netherlands Vaccine Institute; Nobilon International
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 30 Aug 2011 Discontinued - Preclinical for Respiratory syncytial virus infections in Netherlands (Intranasal)
- 10 Nov 2009 This programme is still in active development
- 19 Nov 2007 Nobilon International has been acquired by Schering-Plough